Clinical Trial Update: Safety and Efficacy of PRO 542 in the Treatment of HIV-Infected Patients [Phase 2]

View source ↗

Summary

Phase 2 trial update on PRO 542 for HIV infection and AIDS reports safety and efficacy data from the study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Immunodeficiency Syndrome
• HIV Infection

Drugs mentioned

• PRO 542

Snippet

Sponsor: Progenics Pharmaceuticals, Inc. | Conditions: HIV Infections, Acquired Immune Deficiency Syndrome | Phase 2 | Status: COMPLETED